Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of ABBV-303 alone or in combination with Budigalimab (ABBV-181) in adults with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ABBV-303
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Solid Tumors | Phase 1 | Status: TERMINATED